Skip to main content
OpenTrials
Completed

NCT Number: NCT01144507

Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis

The specific aims for this study are:

1. To determine if sonographic findings predict the risk of progression of liver disease to cirrhosis by comparing cystic fibrosis subjects with heterogeneous echogenicity pattern on ultrasound to those with normal echogenicity pattern on ultrasound 2. To develop a database and biorepository of serum, plasma, urine and DNA to aid the investigations in ascertaining the mechanisms, consequences, genetic risk factors and biomarkers for the development of cirrhosis 3. To determine if there are differences in health related quality of life, pulmonary or nutritional status in children with cystic fibrosis who have a heterogeneous echo pattern on ultrasound compared to those who have a normal echo pattern on ultrasound 4. To determine if Doppler velocity measurements of hepatic and splenic vessels predict an increased risk for the development of cirrhosis. 5. To determine if cirrhosis on ultrasound progresses to portal hypertension during the study period 6. To determine if homogeneous liver progresses to either cirrhosis or heterogeneous liver. 7. To determine the frequency of complications of portal hypertension during follow up in those identified with cirrhosis by year 6 of the study

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Exocrine Pancreatic Insufficiency Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Pancreatic Insufficiency Respiratory Tract Diseases

Age range

3 year–12 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital for Sick Children, Toronto, Ontario, Canada

Loading trial locations.

About this study

For subjects in longitudinal follow up, this study will:

  • Collect detailed clinical and demographic information about each subject at enrollment and during follow up,
  • Obtain and store imaging data from the subject at entry and during follow up,
  • Obtain and store serum, plasma and urine samples from the subject at entry (after matching) and during follow up,
  • Obtain and store DNA from the subject,
  • Obtain and store DNA from the biological parents,
  • Obtain and store quality of life data from the subject and parents at enrollment and during follow up

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children aged 3 through 12 years of age at time of enrollment diagnosed with Cystic Fibrosis and pancreatic insufficiency
  • Enrolled in the CFF registry study or Toronto CF Registry
  • CF defined as sweat chloride of >60 mEq/L on one occasion (using the value in the CF registry) or two disease-causing mutations of CFTR with evidence of end organ involvement.
  • Pancreatic insufficient defined as one of the following:
  • CFTR Mutation associated with pancreatic insufficiency
  • Fecal elastase <100 mcg/gm (at any time)
  • 72 hour fecal fat with coefficient of fat absorption <85% (at any time)

Exclusion criteria

  • Known cirrhosis
  • Presence of Burkholderia cepacia
  • Short bowel syndrome defined as not on full enteral feeds by 3 months of age
  • Presence of other serious disease precluding participation in this study (This would include patients with known other causes of chronic liver disease)
  • If in the opinion of the Investigator the study is not in the best interest of the patient
  • Inability to comply with the longitudinal follow-up described below
  • Failure of a family to sign the informed consent document or the HIPAA medical record release form

Treatment and study plan

Abdominal ultrasound

Procedure

To establish eligibility and/or markers regarding echo pattern types.

Other names: Doppler Ultrasound

Sample collection procedures

Other

Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects

Other names: Doppler Ultrasound

Primary outcomes

  1. Development of cirrhosis, as defined by imaging criteria

    Time frame: Nine years

    The primary objective of this prospective longitudinal study is to determine the utility of abdominal ultrasound (US) at enrollment to predict the development of cirrhosis in subjects with cystic fibrosis (CF) within a nine year period.

Secondary outcomes

  1. Effects on associated pulmonary and nutritional issues

    Time frame: 9years

    • Health related quality of life
    • Growth (length, weight and BMI Z-score, anthropometrics)
    • AST,ALT,GGTP
    • FEV1, FVC
    • Sputum Culture (Pseudomonas, Burkholderia cepacia)
    • Use of IV antibiotics
    • Hospitalization for treatment of pulmonary exacerbation
    • CBC (WBC, Hbg, ANC, platelet count)
    • Fat soluble vitamin levels (Vitamin E, 25 hydroxy vitamin D, Vitamin A)

Sponsors and collaborators

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Nih

Collaborators

  • Cystic Fibrosis Foundation

Registry information

Official study title

Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)

Acronym: PUSH

Important dates

Study start
2010
Primary completion
2021
Study completion
2023
First posted
Jun 15, 2010
Registry last updated
Apr 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.